تداخلات نيفيرابين

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (نشرة أبريميلاست، التحذيرات والاحتياطات)

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. (نشرة أبيراتيرون، التداخلات الدوائية)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (نشرة أبيكسابان، التداخلات الدوائية)

All other drug interactions shown are predicted. ↓ Atazanavir ↑ Nevirapine Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures. (نشرة نيفيرابين، التداخلات الدوائية)

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [See Warnings and Precautions (5. (نشرة أديفوفير، تحذير مؤطر)

CYP3A4 Inducers : Avoid concomitant use for greater than 14 days ( 7.1 ) (نشرة أريبيبرازول، التداخلات الدوائية)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (نشرة أكالابروتينيب، التداخلات الدوائية)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (نشرة ألبيليسيب، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (نشرة إليكساكافتور وتيزاكافتور وإيفاكافتور، التحذيرات والاحتياطات)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Therapy with BARACLUDE is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) [see Warnings and Precautions (5.2) ] . (نشرة إنتيكافير، تحذير مؤطر)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (نشرة أوباداسيتينيب، التداخلات الدوائية)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (نشرة أوبروجيبانت، التداخلات الدوائية)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (نشرة أوكسيكودون، تحذير مؤطر)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (نشرة أوكسيكودون وباراسيتامول، تحذير مؤطر)

Ella should not be administered with CYP3A4 inducers [see Drug interactions (7.1) and Clinical Pharmacology (12.3) ] . (نشرة أوليبريستال، التحذيرات والاحتياطات)

If a CYP3A4 inducer is discontinued, consider OLINVYK dosage reduction and monitor for signs of respiratory depression. (نشرة أوليسيريدين، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Itraconazole ↓ Itraconazole Nevirapine and itraconazole should not be administered concomitantly due to potential decreases in itraconazole plasma concentrations that may reduce efficacy of the drug. (نشرة نيفيرابين، التداخلات الدوائية)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (نشرة إيرينوتيكان، التداخلات الدوائية)

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (نشرة إيفابرادين، التداخلات الدوائية)

Co-administration of nevirapine and efavirenz is not recommended as this combination has been associated with an increase in adverse reactions and no improvement in efficacy. (نشرة نيفيرابين، التحذيرات والاحتياطات)

Co-administration of nevirapine and efavirenz is not recommended as this combination has been associated with an increase in adverse reactions and no improvement in efficacy. (نشرة نيفيرابين، التحذيرات والاحتياطات)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة باراسيتامول وكودايين، تحذير مؤطر)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (نشرة بازوبانيب، التداخلات الدوائية)

• CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (نشرة بالبوسيكليب، التداخلات الدوائية)

Strong CYP3A4 and P-glycoprotein (P-gp) inducers : Avoid using a strong inducer of CYP3A4 and/or P-gp during a dosing interval for ERZOFRI. (نشرة باليبيريدون، التداخلات الدوائية)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (نشرة برازيكوانتيل، موانع الاستعمال)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (نشرة بروميثازين وكودايين، تحذير مؤطر)

Therefore, use of prednisone to prevent nevirapine-associated rash is not recommended. (نشرة نيفيرابين، التحذيرات والاحتياطات)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (نشرة بوبرينورفين، التداخلات الدوائية)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، تحذير مؤطر)

Strong CYP3A4 Inducers: Avoid concomitant use. (نشرة بورتيزوميب، التداخلات الدوائية)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (نشرة بوسوتينيب، التداخلات الدوائية)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in meperidine plasma concentration. (نشرة بيثيدين، تحذير مؤطر)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID. (نشرة بيمافانسيرين، التداخلات الدوائية)

Strong CYP3A4 inducers (e.g., rifampin): Avoid use of HETLIOZ in combination with rifampin or other CYP3A4 inducers, because of decreased exposure ( 7.2 , 12.3 ) (نشرة تاسيملتيون، التداخلات الدوائية)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (نشرة تاموكسيفين، التداخلات الدوائية)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (نشرة ترابيكتيدين، التداخلات الدوائية)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (نشرة ترامادول، تحذير مؤطر)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (نشرة ترامادول وباراسيتامول، تحذير مؤطر)

Avoid concomitant use with strong CYP3A inducers if possible. (نشرة تريتينوين، التداخلات الدوائية)

Coadministration with a strong CYP3A4 inducer may result in a relevant decrease in FARESTON exposure and should be avoided. (نشرة توريميفين، التداخلات الدوائية)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (نشرة تولفابتان، التداخلات الدوائية)

• Avoid use with strong CYP3A inhibitors or CYP3A inducers. (نشرة تيكاغريلور، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (نشرة ثيوتيبا، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (نشرة داريدوريكسانت، التداخلات الدوائية)

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (نشرة داساتينيب، التداخلات الدوائية)

• CYP3A inducers: Avoid concomitant use. (نشرة درونيدارون، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (نشرة دوكسوروبيسين، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy ( 7.1 ) (نشرة ديفلازاكورت، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1)] Taking inducers of CYP3A [see Drug Interactions (7.1)] With liver cirrhosis [see Use in Specific Populations (8.6)] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) (نشرة رانولازين، موانع الاستعمال)

• Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (نشرة روفلوميلاست، التحذيرات والاحتياطات)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (نشرة رولابيتانت، التداخلات الدوائية)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (نشرة روميديبسين، التداخلات الدوائية)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (نشرة ريتليسيتينيب، التداخلات الدوائية)

Fosamprenavir ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. (نشرة نيفيرابين، التداخلات الدوائية)

Therefore, co-administration with antiretroviral and anti-HCV drugs metabolized by CYP3A is not recommended or there may be a need to increase the dose of antiretroviral or anti-HCV drugs (see PRECAUTIONS-Drug Interactions ). (نشرة ريفابوتين، التحذيرات)

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] . (نشرة ريفاروكسابان، التحذيرات والاحتياطات)

Rifampin ↓ Nevirapine Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug. (نشرة نيفيرابين، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (نشرة ريميجيبانت، التداخلات الدوائية)

John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. (نشرة زولبيديم، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (نشرة سورافينيب، التداخلات الدوائية)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (نشرة سيروليموس، التحذيرات والاحتياطات)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (نشرة فالبينازين، التداخلات الدوائية)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (نشرة فليبانسيرين، التداخلات الدوائية)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (نشرة فنتانيل، تحذير مؤطر)

Fosamprenavir ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. (نشرة نيفيرابين، التداخلات الدوائية)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (نشرة فيبديغيسترانت، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (نشرة كابوزانتينيب، التداخلات الدوائية)

Intervention: Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended [see Dosage and Administration ( 2.1 , 2.6 ) ] . (نشرة كاريبرازين، التداخلات الدوائية)

Antiviral and antiretroviral drugs: Avoid concomitant use. (نشرة كلادريبين، التداخلات الدوائية)

• Concomitant use of Strong CYP3A4 Inducers is not recommended. (نشرة كلوزابين، التداخلات الدوائية)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة كودايين، تحذير مؤطر)

Ketoconazole ↓ Ketoconazole Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug. (نشرة نيفيرابين، التداخلات الدوائية)

Avoid strong CYP3A4 inducers. (نشرة لاباتينيب، التداخلات الدوائية)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (نشرة لاروتريكتينيب، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Fosamprenavir ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. (نشرة نيفيرابين، التداخلات الدوائية)

Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. (نشرة لوراسيدون، موانع الاستعمال)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (نشرة لورلاتينيب، التداخلات الدوائية)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (نشرة لوماتيبيرون، التداخلات الدوائية)

Consider alternative HCV or antiretroviral therapy to avoid increases in tenofovir exposures. (نشرة ليديباسفير وسوفوسبوفير، التداخلات الدوائية)

Strong or moderate CYP3A inducers: Avoid concomitant use. (نشرة ليمبوريكسانت، التداخلات الدوائية)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (نشرة نيفيرابين، تحذير مؤطر)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (نشرة ماسيتنتان، التداخلات الدوائية)

CYP3A inducers: Do not use mifepristone with CYP3A inducers ( 7.3 ). (نشرة ميفيبريستون، التداخلات الدوائية)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (نشرة نالديميدين، التداخلات الدوائية)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (نشرة نالوكسيغول، التداخلات الدوائية)

نبتة سانت جون قد تخفض مستويات بعض أدوية فيروس HIV في الدم بما يكفي للتسبب في فشل العلاج. (NCCIH, St. John's Wort)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) -- - ---------- ------ USE IN SPECIFIC POPULATIONS---- -- -- --------- ---- Lactation: Not recommended; Lo Loestrin Fe can decrease milk production ( 8.2 ) (نشرة نوريثيستيرون وإيثينيل إستراديول، التداخلات الدوائية)

Fosamprenavir ↓ Amprenavir ↑ Nevirapine Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. (نشرة نيفيرابين، التداخلات الدوائية)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (نشرة نيفيديبين، التداخلات الدوائية)

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA. (نشرة نيلوتينيب، التداخلات الدوائية)

Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis Pancreatitis (including fatal cases) have occurred in patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine. (نشرة هيدروكسي يوريا، التداخلات الدوائية)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (نشرة هيدروكودون، تحذير مؤطر)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (نشرة هيدروكودون وإيبوبروفين، تحذير مؤطر)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (نشرة هيدروكودون وباراسيتامول، تحذير مؤطر)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (نشرة هيدروكودون وكلورفينيرامين، تحذير مؤطر)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (نشرة هيدروكودون وهوماتروبين، تحذير مؤطر)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

CYP3A4 Inducers Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure [see Clinical Pharmacology (12.3) ]. (نشرة إرلوتينيب، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Alternatives to clarithromycin, such as azithromycin, should be considered. (نشرة نيفيرابين، التداخلات الدوائية)

While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations. (نشرة إستازولام، التحذيرات)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (نشرة إسزوبيكلون، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

CYP3A4/5 Inducers Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. (نشرة أكسيتينيب، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

• Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam. (نشرة ألبرازولام، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (نشرة أورليستات، التحذيرات والاحتياطات)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )]. (نشرة أوميبرازول، التداخلات الدوائية)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )] . (نشرة أوميبرازول وبيكربونات الصوديوم، التداخلات الدوائية)

Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (نشرة أوندانسيترون، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ] . (نشرة إيزوميبرازول، التداخلات الدوائية)

Concomitant Use with CYP3A Inducers Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO. (نشرة إيفاكافتور، التحذيرات والاحتياطات)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (نشرة إيفوسفاميد، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (نشرة إيماتينيب، التداخلات الدوائية)

The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary. (نشرة إيميبرامين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with pantoprazole may reduce antiviral effect and promote the development of drug resistance. (نشرة بانتوبرازول، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (نشرة بريدنيزولون، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (نشرة بريكسبيبرازول، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (نشرة نيفيرابين، التداخلات الدوائية)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (نشرة بوسبيرون، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (نشرة بيتوليسانت، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (نشرة بيكساغليفلوزين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure ( 2.7 , 5.10 , 7.2 ) requiring dose adjustment: CIALIS for use as needed: no more than 10 mg every 72 hours CIALIS for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure ( 7.2 ). (نشرة تادالافيل، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (نشرة ترازودون، التداخلات الدوائية)

Strong Inducers of CYP 3A Clinical implication Coadministration of triazolam with strong inducers of CYP3A4 can significantly decrease the plasma concentration of triazolam and may decrease effectiveness of triazolam. (نشرة تريازولام، التداخلات الدوائية)

Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (نشرة تريامسينولون، التداخلات الدوائية)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (نشرة تيربينافين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (نشرة تيمسيروليموس، التحذيرات والاحتياطات)

CYP3A4 inducers/inhibitors: Monitor for decreased tinidazole effect or increased adverse reactions ( 7.2 ) (نشرة تينيدازول، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

DRUG INTERACTIONS Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. (نشرة ثيوثيكسين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (نشرة دوكسيركالسيفيرول، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance . (نشرة ديكسلانسوبرازول، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance. (نشرة رابيبرازول، التداخلات الدوائية)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (نشرة راميلتيون، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (نشرة روكسوليتينيب، التداخلات الدوائية)

CYP2C8 and CYP3A4 Inducers Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co‑administered. (نشرة ريباغلينيد، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (نشرة ريسبيريدون، التداخلات الدوائية)

Fixed-Dose Combination of Efavirenz, Emtricitabine, and Tenofovir Once-weekly coadministration of 900 mg PRIFTIN with the antiretroviral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in HIV-infected patients did not result in any substantial change in steady state exposures of efavirenz, emtricitabine,… (نشرة ريفابنتين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (نشرة زاليبلون، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Pharmacokinetic Interactions Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. (نشرة زيبراسيدون، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Strong CYP3A inducers: Efficacy may be reduced ( 7.2 ). (نشرة سوفوريكسانت، التداخلات الدوائية)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (نشرة سونيتينيب، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Cancer Chemotherapy: Cyclophosphamide Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (نشرة سيليجيلين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

…and its plasma concentrations can be significantly affected resulting in an increase in exposure Consider dose reduction [see Dosage and administration (2.7) ] Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure… (نشرة غوانفاسين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (نشرة غيفيتينيب، التداخلات الدوائية)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (نشرة نيفيرابين، التداخلات الدوائية)

CYP3A4 Interactions: Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4; see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of FOCINVEZ and concomitant drugs. (نشرة فوسابريبيتانت، التحذيرات والاحتياطات)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

CYP3A4 Inducers No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. (نشرة فيسوتيرودين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days ( 2.4 , 7 ). (نشرة فيلازودون، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Phenobarbital Clinical Impact: Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen. (نشرة فينوبروفين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

…Inducers of Hepatic CYP Enzymes Adults : When Caspofungin acetate for Injection is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of Caspofungin acetate for Injection should be considered [see Dosage and Administration… (نشرة كاسبوفونجين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (نشرة كاناغليفلوزين، التداخلات الدوائية)

Antibiotics: Clarithromycin ↓ Clarithromycin ↑ 14-OH clarithromycin Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (نشرة نيفيرابين، التداخلات الدوائية)

…several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. (نشرة كلوميبرامين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (نشرة كليندامايسين، التداخلات الدوائية)

• Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7-14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. (نشرة كويتيابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antiepileptics (AEDs) (Carbamazepine, Phenobarbital, and Phenytoin) Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate. (نشرة كينين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance. (نشرة لانسوبرازول، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (نشرة ليناغليبتين، التداخلات الدوائية)

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. (نشرة ليناغليبتين وميتفورمين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Ergot Alkaloids: Ergotamine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (نشرة ميثيل بريدنيزولون، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

John's Wort, tramadol, tryptophan, buspirone Strong CYP3A Inducers Clinical Impact The concomitant use of strong CYP3A inducers with REMERON/REMERONSolTab decreases the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (نشرة ميرتازابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Rifampin (Potent Inducer of CYP3A4) Coadministration of a single 500 mg oral dose of mefloquine and 600 mg of rifampin once daily for 7 days in 7 healthy Thai volunteers resulted in a decrease in the mean C max and AUC of mefloquine by 19% and 68%, respectively, and a decrease in the mean elimination half-life of mefloquine from 305 hours to 113 hours. (نشرة ميفلوكين، التداخلات الدوائية)

Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Antifungals: Fluconazole ↑ Nevirapine Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events. (نشرة نيفيرابين، التداخلات الدوائية)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (نشرة ميمانتين ودونيبيزيل، التداخلات الدوائية)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with esomeprazole magnesium may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]. (نشرة نابروكسين وإيزوميبرازول، التداخلات الدوائية)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Calcium Channel blockers: Diltiazem, nifedipine, verapamil Plasma concentrations may be decreased. (نشرة نيفيرابين، التداخلات الدوائية)

Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (نشرة نينتيدانيب، التداخلات الدوائية)

Drugs that May Decrease Haloperidol Plasma Concentrations Coadministration of haloperidol with potent enzyme inducers of CYP3A4 may gradually decrease the plasma concentrations of haloperidol to such an extent that efficacy may be reduced. (نشرة هالوبيريدول، التداخلات الدوائية)

Concomitant administration of inducers of CYP3A4 may lead to decreases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions, including adrenal crisis. (نشرة هيدروكورتيزون، التداخلات الدوائية)

Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (نشرة نيفيرابين، التداخلات الدوائية)

As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time. (نشرة نيفيرابين، التداخلات الدوائية)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (نشرة إيريبولين، التداخلات الدوائية)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (نشرة دوسيتاكسيل، التداخلات الدوائية)

CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (نشرة ريفاكسيمين، التداخلات الدوائية)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (نشرة ريوسيغوات، التداخلات الدوائية)

Antiretrovirals: atazanavir lopinavir ↑ voxilaprevir Coadministration of VOSEVI with atazanavir- or lopinavir-containing regimens is not recommended. tipranavir/ritonavir ↓ sofosbuvir ↓ velpatasvir Coadministration is not recommended. (نشرة سوفوسبوفير وفيلباتاسفير، التداخلات الدوائية)

Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (نشرة غليسرول فينيل بوتيرات، التداخلات الدوائية)

Concurrent use of strong CYP3A inducers (e.g., St. (نشرة فينكريستين، التداخلات الدوائية)

Drugs Having No Clinically Important Interactions with SAPHRIS No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions ( 7.1 ) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin). (نشرة أسينابين، التداخلات الدوائية)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (نشرة مونتيلوكاست، التداخلات الدوائية)

CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. (نشرة ميكافونجين، التداخلات الدوائية)